ATE487470T1 - Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse - Google Patents

Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse

Info

Publication number
ATE487470T1
ATE487470T1 AT03816299T AT03816299T ATE487470T1 AT E487470 T1 ATE487470 T1 AT E487470T1 AT 03816299 T AT03816299 T AT 03816299T AT 03816299 T AT03816299 T AT 03816299T AT E487470 T1 ATE487470 T1 AT E487470T1
Authority
AT
Austria
Prior art keywords
active agent
solid
dosage form
gel
active compositions
Prior art date
Application number
AT03816299T
Other languages
German (de)
English (en)
Inventor
Simon Mcgurk
David Czekai
Original Assignee
Elan Pharma Int Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd filed Critical Elan Pharma Int Ltd
Application granted granted Critical
Publication of ATE487470T1 publication Critical patent/ATE487470T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Yarns And Mechanical Finishing Of Yarns Or Ropes (AREA)
AT03816299T 2002-09-11 2003-09-11 Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse ATE487470T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40958702P 2002-09-11 2002-09-11
PCT/US2003/028380 WO2005000265A2 (en) 2002-09-11 2003-09-11 Gel-stabilized nanoparticulate active agent compositions

Publications (1)

Publication Number Publication Date
ATE487470T1 true ATE487470T1 (de) 2010-11-15

Family

ID=33551184

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03816299T ATE487470T1 (de) 2002-09-11 2003-09-11 Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse

Country Status (13)

Country Link
US (1) US7713551B2 (enExample)
EP (1) EP1553927B9 (enExample)
JP (1) JP4878839B2 (enExample)
AT (1) ATE487470T1 (enExample)
AU (1) AU2003304237A1 (enExample)
CA (1) CA2498207C (enExample)
CY (1) CY1110949T1 (enExample)
DE (1) DE60334924D1 (enExample)
DK (1) DK1553927T3 (enExample)
ES (1) ES2355723T3 (enExample)
PT (1) PT1553927E (enExample)
SI (1) SI1553927T1 (enExample)
WO (1) WO2005000265A2 (enExample)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080102121A1 (en) * 1998-11-02 2008-05-01 Elan Pharma International Limited Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
KR20070051953A (ko) * 1998-11-02 2007-05-18 엘란 코포레이션, 피엘씨 다입자 변형 방출 조성물
US20080113025A1 (en) * 1998-11-02 2008-05-15 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
WO2001034119A2 (en) * 1999-11-12 2001-05-17 Abbott Laboratories Inhibitors of crystallization in a solid dispersion
US20030206958A1 (en) * 2000-12-22 2003-11-06 Cattaneo Maurizio V. Chitosan biopolymer for the topical delivery of active agents
US7758890B2 (en) 2001-06-23 2010-07-20 Lyotropic Therapeutics, Inc. Treatment using dantrolene
US7923431B2 (en) 2001-12-21 2011-04-12 Ferrosan Medical Devices A/S Haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis
PT1471887E (pt) * 2002-02-04 2010-07-16 Elan Pharma Int Ltd ComposiãŽes de nanopartculas com lisozima como um estabilizador superficial
US20050267222A1 (en) * 2002-10-22 2005-12-01 Dainippon Pharmaceutical Co. Ltd. Stabilized composition
MXPA05006193A (es) * 2002-12-11 2005-12-05 Ferrosan As Materiales basados en gelatina como hisopos.
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AR054637A1 (es) * 2004-01-30 2007-07-11 Ferrosan As Aerosoles y composiciones hemostaticas
JP2007536259A (ja) * 2004-05-06 2007-12-13 イヴレア ファーマスーティカルズ インコーポレイテッド 活性薬剤の送達のための粒子
RU2369408C2 (ru) * 2004-07-09 2009-10-10 Ферросан А/С Гемостатическая композиция, включающая гиалуроновую кислоту
DE102004041340A1 (de) * 2004-08-20 2006-02-23 Deutsche Gelatine-Fabriken Stoess Ag Nanopartikel und Verfahren zu deren Herstellung
UA89513C2 (uk) * 2004-12-03 2010-02-10 Элан Фарма Интернешнл Лтд. Стабільна композиція з наночастинок ралоксифену гідрохлориду
EP2353590A1 (en) * 2005-02-15 2011-08-10 Elan Pharma International Limited Aerosol and injectable formulations of nanoparticulate benzodiazepine
CA2598288A1 (en) * 2005-03-03 2006-09-14 Elan Pharma International Limited Nanoparticulate compositions of heterocyclic amide derivatives
WO2006132752A1 (en) * 2005-05-10 2006-12-14 Elan Pharma International Limited Nanoparticulate and controlled release compositions comprising vitamin k2
MX2007014163A (es) * 2005-05-10 2008-01-24 Elan Pharma Int Ltd Formulaciones de nanoparticulas de clopidogrel.
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CN101232870A (zh) * 2005-06-03 2008-07-30 伊兰制药国际有限公司 纳米微粒甲磺酸伊马替尼制剂
AU2006309295B2 (en) * 2005-06-03 2012-04-26 Elan Pharma International Limited Nanoparticulate acetaminophen formulations
WO2007037790A2 (en) * 2005-06-08 2007-04-05 Elan Corporation, Plc Modified release famciclovir compositions
DE112006001606T5 (de) 2005-06-08 2009-07-09 Elan Pharma International Ltd., Athlone Nanopartikuläre und eine kontrollierte Freisetzung aufweisende Zusammensetzung, die Cefditoren umfassen
ATE446742T1 (de) * 2005-06-09 2009-11-15 Elan Pharma Int Ltd Nanopartikuläre ebastinformulierungen
BRPI0611626A2 (pt) * 2005-06-13 2010-09-21 Elan Pharma Int Ltd formulações da combinação de nanopartìculas de clopidogrel e aspirina
WO2006138421A2 (en) * 2005-06-15 2006-12-28 Elan Pharma International Limited Nanoparticulate azelnidipine formulations
US9119899B2 (en) * 2006-01-18 2015-09-01 Cormatrix Cardiovascular, Inc. Method and system for treatment of cardiovascular disorders
WO2007033239A2 (en) * 2005-09-13 2007-03-22 Elan Pharma International, Limited Nanoparticulate tadalafil formulations
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
MX336930B (es) 2005-11-28 2016-02-05 Marinus Pharmaceuticals Formulaciones de ganaxolona y metodos para la manufactura y el uso de las mismas.
EP1954241B1 (en) * 2005-11-28 2012-02-29 Orexigen Therapeutics, Inc. Sustained-release formulation of zonisamide
US20090215753A1 (en) * 2005-12-07 2009-08-27 Pharmacodex Ltd. Topical Compositions for Paediatric Use
ZA200805192B (en) 2005-12-29 2009-11-25 Lexicon Pharmaceuticals Inc Multicyclic amino acid derivatives and methods of their use
US7649098B2 (en) 2006-02-24 2010-01-19 Lexicon Pharmaceuticals, Inc. Imidazole-based compounds, compositions comprising them and methods of their use
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
ES2448472T3 (es) * 2006-05-26 2014-03-14 José Antonio Cruz Serrano Gel de proteína y procedimiento para su elaboración
BRPI0712130A2 (pt) 2006-05-30 2012-01-17 Elan Pharma Int Ltd formulações de posaconazol em nanopartìculas
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2032137A2 (en) * 2006-06-23 2009-03-11 Elan Pharma International Limited Compositions comprising nanoparticulate naproxen and controlled release hydrocodone
EP2049084A2 (en) * 2006-07-10 2009-04-22 Elan Pharma International Limited Nanoparticulate sorafenib formulations
KR100809903B1 (ko) 2006-09-05 2008-03-06 주식회사유한양행 안정화된 클로피도그렐-함유 입자, 그의 제조방법, 및 이를포함하는 약학 조성물
KR101971218B1 (ko) 2006-11-09 2019-08-27 오렉시젠 세러퓨틱스 인크. 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형
US20080110792A1 (en) * 2006-11-09 2008-05-15 Orexigen Therapeutics, Inc. Methods for administering weight loss medications
WO2008066899A2 (en) 2006-11-28 2008-06-05 Marinus Pharmaceuticals Nanoparticulate formulations and methods for the making and use thereof
UA99270C2 (en) 2006-12-12 2012-08-10 Лексикон Фармасьютикалз, Инк. 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
EP2137182A1 (en) * 2007-03-16 2009-12-30 Elan Pharma International Limited Combination of a narcotic and a non-narcotic analgesic
KR100761041B1 (ko) 2007-03-22 2007-10-04 현대약품 주식회사 산 불안정성 벤즈이미다졸계 화합물을 포함하는 약학조성물
KR100761040B1 (ko) 2007-03-22 2007-10-04 현대약품 주식회사 산 불안정성 벤즈이미다졸계 화합물을 포함하는 약학조성물
WO2008124764A1 (en) * 2007-04-10 2008-10-16 Saint Simeon Lda Novel compositions containing lysozyme and c-1/c-4 polysaccharides and use thereof in oral care, cosmetology and dermatology, contraception, urology and gynecology
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
US20120164226A1 (en) * 2007-06-11 2012-06-28 Leuthner Brian A Compositions and Methods for Improving Prognosis of a Human with Subarachnoid Hemorrhage
US10092524B2 (en) 2008-06-11 2018-10-09 Edge Therapeutics, Inc. Compositions and their use to treat complications of aneurysmal subarachnoid hemorrhage
PT103765A (pt) * 2007-06-20 2008-12-22 Inst Superior Tecnico Síntese e aplicação de uma família de novos materiais resultantes do cruzamento entre gelatina e sais orgânicos
EP2227212A1 (en) * 2007-12-07 2010-09-15 BioCure, Inc. Bone substitute
US20090155363A1 (en) * 2007-12-14 2009-06-18 Todd Maibach Methods for oral administration of active drugs
CA2716872C (en) 2008-02-29 2015-02-10 Ferrosan Medical Devices A/S Device for promotion of hemostasis and/or wound healing
US8389012B2 (en) * 2008-03-07 2013-03-05 The Corporation Of Mercer University Gellan-gum nanoparticles and methods of making and using the same
WO2009117401A2 (en) * 2008-03-21 2009-09-24 Elan Pharama International Limited Compositions for site-specific delivery of imatinib and methods of use
MX2010012909A (es) * 2008-05-30 2011-02-25 Orexigen Therapeutics Inc Metodos para tratamiento de condiciones de grasa visceral.
US9498440B2 (en) 2009-05-22 2016-11-22 Inventia Healthcare Private Limited Extended release pharmaceutical compositions
EP3167875A1 (en) * 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
SG177281A1 (en) * 2009-06-19 2012-02-28 Nanoform Hungary Ltd Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them
US9775819B2 (en) * 2009-09-16 2017-10-03 R.P. Scherer Technologies, Llc Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
CA2779681A1 (en) 2009-11-05 2011-05-12 Lexicon Pharmaceuticals, Inc. Tryptophan hydroxylase inhibitors for the treatment of cancer
KR101841442B1 (ko) * 2010-01-11 2018-03-23 오렉시젠 세러퓨틱스 인크. 주우울증 환자들에 있어서 체중 감량 치료를 제공하는 방법
JP2013519673A (ja) 2010-02-10 2013-05-30 レクシコン ファーマシューティカルズ インコーポレイテッド 転移性骨疾患の治療のためのトリプトファンヒドロキシラーゼ阻害剤
GB201006218D0 (en) * 2010-04-14 2010-06-02 Ayanda As Composition
US9012511B2 (en) 2010-05-19 2015-04-21 Alkermes Pharma Ireland Limited Nanoparticulate cinacalcet compositions
SG188509A1 (en) 2010-09-13 2013-04-30 Bev Rx Inc Aqueous drug delivery system comprising off - flavor masking agent
US9532952B2 (en) 2011-01-28 2017-01-03 Physician's Seal, LLC Controlled-release compositions of melatonin combined with sedative and/or analgesic ingredients
WO2012103411A2 (en) 2011-01-28 2012-08-02 Zx Pharma, Llc Controlled-release melatonin composition and related methods
SG10201602665UA (en) 2011-04-05 2016-05-30 Edge Therapeutics Intraventricular Drug Delivery System For Improving Outcome After A Brain Injury Affecting Cerebral Blood Flow
CA2833105C (en) * 2011-04-11 2019-04-23 Ayanda Group As Oral pharmaceutical dispersion compositions
EP2540287A1 (en) 2011-07-01 2013-01-02 FutureChemistry Continuous flow production of gelatin nanoparticles
JP5991978B2 (ja) * 2011-09-09 2016-09-14 東洋カプセル株式会社 カンデサルタンシレキセチル含有医薬組成物
CA2865349C (en) 2012-03-06 2021-07-06 Ferrosan Medical Devices A/S Pressurized container containing haemostatic paste
AU2013235266B2 (en) 2012-03-20 2017-10-19 Particle Dynamics International, Llc Gelling agent-based dosage form
US20130303763A1 (en) 2012-03-30 2013-11-14 Michael D. Gershon Methods and compositions for the treatment of necrotizing enterocolitis
IL300868A (en) 2012-06-06 2023-04-01 Orexigen Therapeutics Inc Methods for treating overweight and obesity
RU2636240C2 (ru) 2012-06-12 2017-11-21 Ферросан Медикал Дивайсиз А/С Сухая гемостатическая композиция
FR2999086B1 (fr) * 2012-12-10 2015-04-10 Ethypharm Sa Composition orale et/ou buccale sous forme de film fin d'un principe actif faiblement soluble, son procede de preparation et son utilisation
EP3010419B1 (en) 2013-06-21 2020-05-20 Ferrosan Medical Devices A/S Vacuum expanded dry composition and syringe for retaining same
WO2015089105A1 (en) 2013-12-09 2015-06-18 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
BR112016013322B1 (pt) 2013-12-11 2020-07-21 Ferrosan Medical Devices A/S métodos para preparação de uma composição seca e para reconstituir uma composição seca, composição seca, uso de uma composição seca, e, kit
RU2715235C2 (ru) 2014-10-13 2020-02-26 Ферросан Медикал Дивайсиз А/С Сухая композиция для использования при гемостазе и заживлении ран
CA2970710A1 (en) 2014-12-24 2016-06-30 Ferrosan Medical Devices A/S Syringe for retaining and mixing first and second substances
KR20160081646A (ko) * 2014-12-31 2016-07-08 건일제약 주식회사 멜라토닌 및 설트랄린을 포함하는 경구용 복합정제
CN105981748B (zh) * 2015-05-07 2018-12-04 博约生物科技(苏州)有限公司 一种提取天然抑菌剂有效成分的方法
CN107771093B (zh) 2015-07-03 2021-06-15 弗罗桑医疗设备公司 用于混合两种组分和用于在存储条件下保持真空的注射器
MX2018004376A (es) 2015-10-16 2018-08-01 Marinus Pharmaceuticals Inc Formulaciones inyectables de neuroesteroides que contienen nanoparticulas.
KR102518846B1 (ko) 2016-08-11 2023-04-05 오비드 테라퓨틱스 인크. 간질 장애의 치료를 위한 방법 및 조성물
US10391105B2 (en) 2016-09-09 2019-08-27 Marinus Pharmaceuticals Inc. Methods of treating certain depressive disorders and delirium tremens
EP3694491A1 (en) 2017-10-10 2020-08-19 Capsugel Belgium NV Gelling multiparticulates
CN112368028A (zh) 2018-05-09 2021-02-12 弗罗桑医疗设备公司 用于制备止血组合物的方法
US11266662B2 (en) 2018-12-07 2022-03-08 Marinus Pharmaceuticals, Inc. Ganaxolone for use in prophylaxis and treatment of postpartum depression
CA3145923A1 (en) 2019-08-05 2021-02-11 David Czekai Ganaxolone for use in treatment of status epilepticus
AU2020395254A1 (en) 2019-12-06 2022-06-02 Marinus Pharmaceuticals, Inc. Ganaxolone for use in treating tuberous sclerosis complex
US11071739B1 (en) 2020-09-29 2021-07-27 Genus Lifesciences Inc. Oral liquid compositions including chlorpromazine
EP4122453A1 (en) * 2021-07-22 2023-01-25 Universität Heidelberg Thermoreversible gelatin matrix for stability enhancement and ready-to-use liquid application of nanoparticles and colloidal drugs
EP4486719A1 (en) 2022-03-02 2025-01-08 Horizon Therapeutics Ireland DAC Process of making a crystalline edg-2 receptor antagonist
CN117186267B (zh) * 2022-05-31 2025-01-28 杭州协合医疗用品有限公司 一种羟丁基甲壳素、羟丁基甲壳素水凝胶及制备方法
KR20250149910A (ko) * 2024-04-10 2025-10-17 주식회사 인벤테라 림프관으로 배출 가능하고 면역원성이 감소된 다당류 가교 콜로이드 입자 기반 기능성 약물

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4003999A (en) * 1972-10-25 1977-01-18 A. H. Robins Company, Incorporated Aspirin-tea coprecipitates for treating inflammation
US4486412A (en) 1983-03-15 1984-12-04 Pharmacaps, Inc. Encapsulated antacid dispersions
US4826689A (en) 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
US4783484A (en) 1984-10-05 1988-11-08 University Of Rochester Particulate composition and use thereof as antimicrobial agent
US4882157A (en) * 1985-12-20 1989-11-21 Yang Robert K Confectionery delivery system for anti-cholesterolemics
US4778676A (en) * 1985-12-20 1988-10-18 Warner-Lambert Company Confectionery delivery system for actives
US4795642A (en) 1986-05-01 1989-01-03 Pharmacaps, Inc. Gelatin-encapsulated controlled-release composition
US4708834A (en) 1986-05-01 1987-11-24 Pharmacaps, Inc. Preparation of gelatin-encapsulated controlled release composition
US4837255A (en) * 1987-03-10 1989-06-06 Ciba-Geigy Corporation Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
US4935243A (en) 1988-12-19 1990-06-19 Pharmacaps, Inc. Chewable, edible soft gelatin capsule
US6482516B1 (en) 1993-07-20 2002-11-19 Banner Pharmacaps, Inc. Enrobed tablet
US5146730A (en) 1989-09-20 1992-09-15 Banner Gelatin Products Corp. Film-enrobed unitary-core medicament and the like
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5399363A (en) 1991-01-25 1995-03-21 Eastman Kodak Company Surface modified anticancer nanoparticles
AU642066B2 (en) 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5552160A (en) 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
AU2317592A (en) 1991-07-05 1993-02-11 University Of Rochester Ultrasmall non-aggregated porous particles entrapping gas-bubbles
US5200191A (en) 1991-09-11 1993-04-06 Banner Gelatin Products Corp. Softgel manufacturing process
EP0615445B1 (de) 1991-12-05 1996-05-15 ALFATEC-PHARMA GmbH Pharmazeutisch applizierbares nanosol und verfahren zu seiner herstellung
DE4140179C2 (de) 1991-12-05 1995-12-21 Alfatec Pharma Gmbh Akutform für ein Ibuprofen enthaltendes Arzneimittel
AU660852B2 (en) 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5349957A (en) 1992-12-02 1994-09-27 Sterling Winthrop Inc. Preparation and magnetic properties of very small magnetite-dextran particles
US5298262A (en) 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5346702A (en) 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5302401A (en) 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5401492A (en) 1992-12-17 1995-03-28 Sterling Winthrop, Inc. Water insoluble non-magnetic manganese particles as magnetic resonance contract enhancement agents
US5326552A (en) 1992-12-17 1994-07-05 Sterling Winthrop Inc. Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
US5264610A (en) 1993-03-29 1993-11-23 Sterling Winthrop Inc. Iodinated aromatic propanedioates
US5718388A (en) 1994-05-25 1998-02-17 Eastman Kodak Continuous method of grinding pharmaceutical substances
TW384224B (en) 1994-05-25 2000-03-11 Nano Sys Llc Method of preparing submicron particles of a therapeutic or diagnostic agent
US5525328A (en) 1994-06-24 1996-06-11 Nanosystems L.L.C. Nanoparticulate diagnostic diatrizoxy ester X-ray contrast agents for blood pool and lymphatic system imaging
US5587143A (en) 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
NZ280610A (en) * 1994-12-29 1997-08-22 Mcneil Ppc Inc Soft gelatin-like pharmaceutical carrier: gelled polyethylene glycol and dispersed active agent
US5585108A (en) 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5466440A (en) 1994-12-30 1995-11-14 Eastman Kodak Company Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
US5628981A (en) 1994-12-30 1997-05-13 Nano Systems L.L.C. Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
US5569448A (en) 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5560931A (en) 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5571536A (en) 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5534270A (en) 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5622938A (en) 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5518738A (en) 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5593657A (en) 1995-02-09 1997-01-14 Nanosystems L.L.C. Barium salt formulations stabilized by non-ionic and anionic stabilizers
US5500204A (en) 1995-02-10 1996-03-19 Eastman Kodak Company Nanoparticulate diagnostic dimers as x-ray contrast agents for blood pool and lymphatic system imaging
US5591456A (en) 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5543133A (en) 1995-02-14 1996-08-06 Nanosystems L.L.C. Process of preparing x-ray contrast compositions containing nanoparticles
US5510118A (en) 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5718919A (en) 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
US5565188A (en) 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
EP0810853B1 (en) 1995-02-24 2004-08-25 Elan Pharma International Limited Aerosols containing nanoparticle dispersions
US5573749A (en) 1995-03-09 1996-11-12 Nano Systems L.L.C. Nanoparticulate diagnostic mixed carboxylic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5643552A (en) 1995-03-09 1997-07-01 Nanosystems L.L.C. Nanoparticulate diagnostic mixed carbonic anhydrides as x-ray contrast agents for blood pool and lymphatic system imaging
US5472683A (en) 1995-03-09 1995-12-05 Eastman Kodak Company Nanoparticulate diagnostic mixed carbamic anhydrides as X-ray contrast agents for blood pool and lymphatic system imaging
US5521218A (en) 1995-05-15 1996-05-28 Nanosystems L.L.C. Nanoparticulate iodipamide derivatives for use as x-ray contrast agents
US5573750A (en) 1995-05-22 1996-11-12 Nanosystems L.L.C. Diagnostic imaging x-ray contrast agents
CN1191480A (zh) 1995-06-09 1998-08-26 R·P·谢勒公司 含颗粒材料的软明胶胶囊
BR9611092A (pt) * 1995-09-19 1999-07-13 Alcan Int Ltd Precipitação de ligas de alumínio endurecido para aplicações estruturais automotivas
US5834025A (en) 1995-09-29 1998-11-10 Nanosystems L.L.C. Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
WO1998035666A1 (en) 1997-02-13 1998-08-20 Nanosystems Llc Formulations of nanoparticle naproxen tablets
US6045829A (en) 1997-02-13 2000-04-04 Elan Pharma International Limited Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
US6197787B1 (en) 1997-03-03 2001-03-06 Sanofi-Synthelabo Pharmaceutical formulations containing poorly soluble drug substances
NL1009107C2 (nl) 1997-11-12 1999-06-15 Banner Pharmacaps Inc Gelatine-uitspreidende doos met meervoudige, aanpasbare poortklep en meerlagig zacht gel.
US6432442B1 (en) * 1998-02-23 2002-08-13 Mcneil-Ppc, Inc. Chewable product
US6153225A (en) 1998-08-13 2000-11-28 Elan Pharma International Limited Injectable formulations of nanoparticulate naproxen
US6165506A (en) * 1998-09-04 2000-12-26 Elan Pharma International Ltd. Solid dose form of nanoparticulate naproxen
JP2002525311A (ja) * 1998-10-01 2002-08-13 エラン ファーマ インターナショナル,リミティド 徐放性ナノ粒子組成物
US8293277B2 (en) 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US6375986B1 (en) 2000-09-21 2002-04-23 Elan Pharma International Ltd. Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
US6258380B1 (en) 1999-03-05 2001-07-10 Banner Pharmacaps, Inc. Chewable soft capsule
US6267989B1 (en) 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000072973A1 (en) 1999-06-01 2000-12-07 Elan Pharma International Ltd. Small-scale mill and method thereof
US6251426B1 (en) 1999-09-02 2001-06-26 Banner Pharmacaps, Inc. Ibuprofen-containing softgels
AU2001257315A1 (en) 2000-04-26 2001-11-20 Elan Pharma International, Ltd. Apparatus for sanitary wet milling
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6685961B1 (en) 2000-10-24 2004-02-03 Banner Pharmacaps, Inc. Colored gelatin-based formulations and method
DE60227802D1 (de) 2001-06-05 2008-09-04 Elan Pharma Int Ltd Mahlvorrichtung und verfahren zu deren betrieb
US6949256B2 (en) 2002-01-18 2005-09-27 Banner Pharmacaps, Inc. Non-gelatin capsule shell formulation
DE10244504A1 (de) * 2002-09-25 2004-04-08 Capsulution Nanoscience Ag Schnellfreisetzende Darreichungsform mit schwerlöslichem Wirkstoff
US20060088590A1 (en) 2004-10-22 2006-04-27 Banner Pharmacaps, Inc. Non-blooming gelatin and non-gelatin formulations
CA2627292C (en) 2005-10-26 2012-04-17 Banner Pharmacaps, Inc. Hydrophilic vehicle-based dual controlled release matrix system
US20070148248A1 (en) 2005-12-22 2007-06-28 Banner Pharmacaps, Inc. Gastric reflux resistant dosage forms

Also Published As

Publication number Publication date
ES2355723T3 (es) 2011-03-30
DE60334924D1 (de) 2010-12-23
WO2005000265A2 (en) 2005-01-06
AU2003304237A1 (en) 2005-01-13
EP1553927B9 (en) 2011-09-21
AU2003304237A8 (en) 2005-01-13
US7713551B2 (en) 2010-05-11
WO2005000265A3 (en) 2005-05-12
JP2006514688A (ja) 2006-05-11
CY1110949T1 (el) 2015-06-10
DK1553927T3 (da) 2011-01-31
JP4878839B2 (ja) 2012-02-15
EP1553927A2 (en) 2005-07-20
US20050031691A1 (en) 2005-02-10
CA2498207A1 (en) 2005-01-06
EP1553927B1 (en) 2010-11-10
PT1553927E (pt) 2010-11-22
CA2498207C (en) 2012-03-13
SI1553927T1 (sl) 2010-12-31

Similar Documents

Publication Publication Date Title
ATE487470T1 (de) Gel-stabilisierte wirkstoff-zusammensetzungen in nanoteilchengrösse
ATE381317T1 (de) Nanopartikuläre zusammensetzungen in form festen darreichungen
EP1781257A4 (en) PHARMACEUTICAL FORMULATIONS WITH MICROPARTICLES OR NANOPARTICLES OF AN AGENT
DE60325718D1 (de) Nystatin-nanopartikelzusammensetzungen
AR040110A1 (es) Formulaciones de fibrato en nanoparticulas
CO5170479A1 (es) Emulsion aceite en agua que comprende un agente biologicamente activo micronizado y un sistema emulsionante adecuado saturado y un mono de ester de acido acrilico. .
BR0107869A (pt) Composições farmacêuticas eletrogiradas
DE69812343D1 (de) Feste pharmazeutische formulierungen enthaltend eine physische mischung aus sulphoalkylethercyclodextrin und einem therapeutischen wirkstoff
CO6150124A2 (es) Composiciones de fenofibrato que contienen nanoparticulas de fenofibrato y metodos para hacerla
AR027091A1 (es) Forma de dosificacion de farmacos accionada por un hidrogel
DE69905380D1 (de) Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen
CY1105908T1 (el) Στοματικως αποσαθρουμενα δισκια που πepιλαμβανουν βενζιμιδαζολιο
ATE478656T1 (de) Biologisch abbaubare polymerzusammensetzungen, zusammensetzungen und damit in beziehung stehende verwendungen
DE60202794D1 (de) Orodispersible tablette mit hoher homogenität und herstellungsverfahren dafür
ATE464880T1 (de) Arzneistoffnanopartikel mit lysozym- oberflächenstabilisator
AR038947A1 (es) Suspension oral de sabor agradable y metodo
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
AR043272A1 (es) Una microparticula recubierta con una sustancia lipofilica que contiene una droga proteica o antigeno y formulaciones que la comprenden
AR038308A1 (es) Composiciones cosmeticas o para el cuidado personal
BR112012016468B1 (pt) Composição de cuidado oral e método para fornecer benefícios de saúde oral para uma superfície oral
ES2074269T3 (es) Preparado de suspension acuoso para inyeccion y metodo para producir el mismo.
JP2006520801A5 (enExample)
EP1365749A4 (en) PROCESS FOR PREPARING PHARMACEUTICAL COMPOSITIONS FOR USE WITH WEICHGELATINE FORMULATIONS
CO2022005947A2 (es) Formulaciones de cápsulas de gelatina blanda no animales, métodos de preparación y métodos de uso de las mismas
DE50007327D1 (de) Antitranspirant-zusammensetzung enthaltend einen wasserlöslichen antitranspirant-wirkstoff

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1553927

Country of ref document: EP